This is very, very niche, but I couldn’t think of a more suitable place so I’ll give it a go.
In the US, brand name medications are outrageously priced. There are deals between payors (PBM/Medicare) and manufacturers that look like this:
Sticker price $20,000/mo minus negotiated insurance payment of $15,000 theoretically leaves pt on the hook for $5.000/mo, BUT…
Manufacturer graciously offers a “coupon” / discount card, which covers a max of $4,995.00, leaving pt with a net responsibility of $5.00/month.
These are convenient numbers to work with, but closely resemble the pricing and coverage structure of a long-term medication I take.
The coupon never results in zero pt responsibility, always leaving some negligible amount due. Invariably, it’s exactly enough money to be a huge pain in everyone’s ass and to make no meaningful difference to anyone involved in the transaction. $5.00 and $9.00 are amounts I see frequently.
Getting to the actual question, why bother?
Seriously, I wasted a half hour of my life waiting on hold to schedule a refill on a specialty med that can only be filled from a single central pharmacy and shipped, to be told that a) they somehow didn’t charge card on file for the $5.00 last month, and b) can’t schedule next shipment until I pay the all-important five bucks. Didn’t have a card close at hand, had to call back later so they could extract their couple dollars and then schedule the next round.
It literally costs them more in toll free charges, infrastructure fixed costs, and salaries to collect that money than they make from it.
I assume the answer is something along the lines of “personal responsibility” and someone in Congress having a stroke over the idea of someone getting medicine for “free,” but I’ve been unable to substantiate that.
Convinced there is a reason, probably buried in a 10,000 page CMS policy manual, because the mfg coupon literally never brings the price to zero. See, e.g., DTC drug commercials referencing “pay as little as $x a month!”
Underrepresented at best, at worst it’s arguably too easy to forget that Alpine is more than just container images.
Not sure how to solve that problem, it’s my go to for rolling an image but wouldn’t normally make the shortlist for standalone machines. In a prod env, that’s basically Deb, RHEL derivatives, etc. In a personal env for me, Arch derivs tend to win out on non-critical services if only because I invariably learn something useful that I wouldn’t want to learn in prod.